Introduction: Our aim was to compare analytical specifications of two assays (monoclonal vs. polyclonal) for free light chains (FLCs) quantification optimized for two different analytical platforms, nephelometer ProSpec (Siemens, Erlangen, Germany) and turbidimetric analyser Optilite (The Binding Site, Birmingham, UK).
Introduction
Monoclonal protein concentration, either synthesized as an intact molecule or part of the immunoglobulin molecule (free light chain (FLC); free heavy chain) is one of the criteria in diagnosis and it is crucial in monitoring plasma cell disorders (1, 2) .
Traditionally used methods for measuring the concentration of M-protein are nephelometry/turbidimetry and densitometer tracing. Although nephelometry and densitometer tracing are recommended methods, there is no evidence that turbidimetry is not a good alternative in the quantification of M-protein (1, 3) .
Nephelometric/turbidimetric tests for measuring FLCs and heavy-light chains routinely used in clinical practice during the past decade represent valuable progress in the diagnosis and monitoring of myeloma patients (4) (5) (6) .
In 2014, International Myeloma Working Group (IMWG) updated the criteria for the diagnosis of multiple myeloma. The revised IMWG criteria, in addition to the classic CRAB criteria (i.e. C -hypercalcaemia: serum calcium > 0.25 mmol/L higher than the upper limit of normal or > 2.75 mmol/L; R -renal insufficiency: creatinine clearance < 40 mL/ min or serum creatinine > 177 μmol/L; A -anaemia: haemoglobin value of > 20 g/L below the lower limit of normal, or a haemoglobin value < 100 g/L; B -bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT) or positron emission tomography-computed tomography (PET-CT), included the newly defined SLiM criteria (i.e. S -≥ 60% clonal bone marrow plasma cells; Li -serum FLC ratio involved/ uninvolved ≥ 100; M -> 1 focal lesion (≥ 5 mm each) detected by MRI studies) (7) . Also, quantification of FLCs is included in international uniform therapeutic response criteria in patients without measurable serum or urine M-protein (6) .
Free light chains antibodies in reagents should react only with exposed FLC epitopes which are hidden when the light chain is bound to the heavy chain. In addition to tests included in this evaluation with polyclonal sheep and monoclonal antibodies at least four different tests, monoclonal or polyclonal origin are available (8) . The first relevant FLCs studies were made with a polyclonal sheep test that is no longer the only one available on the market (6, 9) .
Although the monoclonal reagent is applicable solely on nephelometric analytical platforms, the polyclonal reagent is applicable as an open channel test on various turbidimetric analysers with no exactly defined antigen excess parameters for FLC test and with the need for additional manual dilutions (5).
Taking into account the three most important sources of variability and differences in the results of immunoassays (i.e. prozone effect, cross reactivity and matrix influence) we prepared the verification protocol on Optilite (The Binding Site, Birmingham, UK) and ProSpec (Siemens, Erlangen, Germany) analysers for FLC assays (10) . Optilite is a new generation special protein analyser optimized for The Binding Site (TBS) reagents with reaction kinetic method for identifying antigen excess. ProSpec uses a built-in prereaction protocol to ensure detection of antigen excess (11) . These analytical systems have different ways of detecting the resulting immune complex; Optilite by measuring turbidity and ProSpec by measuring the amount of scattered light. Also, the difference in the reagent composition of these two manufacturers is significant. The Optilite reagent is of polyclonal origin while the Siemens reagent contains monoclonal antibodies.
In tertiary care hospital with preselected haematological patients is of great interest to use the evaluated test and to detect possible discordance of results using different FLC tests. The aim is to present the verification results of two assays for FLCs quantification optimized for two analytical platforms.
Materials and methods

Materials
Analysers Optilite (The Binding Site, Birmingham, United Kingdom) and ProSpec (Siemens, Erlangen, Germany) were included in the verification protocol for measuring FLCs. Tests are performed according to the manufacturer`s instructions and with automated dilutions. The same reagent lot was used during evaluation. Concentration ranges of the used control materials optimized for each reagent were for Level 1 10-30 mg/L and for Level 2 30-60 mg/L. Method comparison study, approved by the hospital ethical committee, included 37 serum samples from outpatients managed at the Department of Hematology during the evaluation week. Kappa and lambda FLC were measured in each sample by both methods and FLC kappa/lambda ratio was calculated.
Methods
The evaluation included precision verification through testing repeatability and reproducibility, estimation of accuracy and comparison of results obtained by the applied methods. Precision was investigated analysing control materials in two concentrations, in triplicates during five days following the Clinical and Laboratory Standard Institute (CLSI) guideline EP-15 A2 (12) . Repeatability was calculated as CV wr (%) using daily standard deviation (S d ) in three replicates, and average standard deviation (S r ) in five runs. . Reproducibility was calculated as CV br (%) by dividing standard deviation (S b ) , calculated from daily means, with an average of all results (grand mean) (13) . Results of precision experiment were compared to with-in run and between run coefficients of variation obtained during manufacturer method validation and with quality goals derived from biological variation data. Optimum, desirable and minimum specifications for imprecision were calculated as follows: I optimum = 0.25 x CV within-subject ; I desirable = 0.50 x CV within-subject ; I minimum = 0.75 x CV within-subject .
Due to the lack of certified reference material (CRM), accuracy was estimated using results from the precision experiment procedure relative to the assigned (target) values of the control materials used in the experiment. Optimum, desirable and minimum specifications for bias were calculated as follows: B optimum = 0.125x (CV within-subject 2 + CV be- Results are categorized also according to criteria for progressive disease where FLC kappa or FLC lambda > 100 mg/L and 0.01 > FLC kappa/lambda ratio > 100 and to 25% and 50% difference in FLC ratio (14) .
In order to clarify the discordance in FLC lambda results in three patient samples, serum protein electrophoresis by Capillarys 2 (Sebia, Lyses, France) was performed. Immunofixation electrophoresis using the Hydrasys system (Sebia, Lyses, France) was performed as a confirmation method for M-protein detection (1) . Immunofixation is done by free kappa (ĸf), free lambda (λf), gamma (γ), kappa (ĸ) and lambda (λ) antisera. Also, in a sample with detected monoclonal immunoglobulin G (IgG), total IgG is measured on Cobas 6000cee (Roche Diagnostics, Rotkreuz, Switzerland).
Statistical analysis
All data sets have been tested for normality using the Kolmogorov-Smirnov test. Table 2 ) and pointed to the existence of constant and proportional error in assays for FLC kappa and proportional error in FLC lambda assays: y = -3. pa/lambda ratio > 100) in 2/37 (0.05) cases progressive disease would not be recognized (weighted Kappa 0.72, P = 0.003) when using one of the applied analysers (Figure 4) .
The difference in FLC kappa/lambda ratios between evaluated assays was greater than 25% in 16/37 (0.43) patients and even equal to or greater than 50% in 13/37 (0.35) patients.
The method comparison graph has revealed three samples with a difference in FLC lambda results greater than twelve times (Figure 3 ). In these samples, the FLC lambda obtained on ProSpec was < 1000 mg/L and on Optilite > 7000 mg/L; the monoclonal synthesis of FLC lambda was confirmed by immunofixation electrophoresis (Table 3) . Even though differences and possible interferences of immunoassays in general are well known, the variability of M-protein structure should be emphasized as an additional challenge in developing an immunoassay for M-protein quantification.
Changes in the plasma cell genome are numerous and substantially heterogeneous, resulting in a protein product of unpredictable structure (5) . In lymphoproliferative diseases, changes in the immunoglobulin molecule may affect both the F c and the F ab domain, thus leading to the inability of using tests which recognize specific epitopes on an immunoglobulin molecule. We hypothesized that methods that include the ability to detect structure equivalence may have a certain advantage in quantifying M-protein.
From our results we can conclude that the use of different FLCs assays, even on reagent-optimized analysers, can in some patients during therapy regimen lead to different categorization of disease progression. Observed differences in clonality marker, FLC ratio represent evidence that these methods should not be used interchangeably. Furthermore, the used method for FLCs should be obligatory information on the laboratory report.
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